Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 686

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 6
Chunk 686
---
 will continue as a going concern. At December 31, 2024, the Company had cash and cash equivalents
of $115,019 and has not yet generated any revenues. Therefore, our ability to continue our operations is highly dependent on our ability
to raise capital to fund future operations. We anticipate, based on currently proposed plans and assumptions, that our cash and cash equivalents
on hand will not satisfy our operational and capital requirements through twelve months from the filing date of this Annual Report on
Form 10-K.

There are a number of uncertainties associated with
our ability to raise additional capital and we have no current arrangements with respect to any additional financing. In addition, the
continuation of disruptions caused by COVID-19 or other variants or pandemics, broad-based inflation, and various economic indicators
that the United States economy may be entering a recession in upcoming quarters may cause investors to slow down or delay their decision
to deploy capital which will adversely impact our ability to fund future operations. Consequently, there can be no assurance that any
additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital
will delay our ability to conduct our business operations. Any additional equity financing may involve substantial dilution to our then
existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going concern.

2.        Summary
of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements
have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and include the
accounts of Mosaic ImmunoEngineering, Inc. and our subsidiaries. All intercompany accounts and transactions among the consolidated entities
have been eliminated in the consolidated financial statements.

     F-8 

    Mosaic ImmunoEngineering, Inc.

    Notes to Consolidated Financial Statements
    For the Years Ended December 31, 2024 and 2023 (continued)

Cash and Cash Equivalents

We consider all highly liquid investments acquired
with a maturity of three months or less from the purchase date to be cash equivalents.

Investment in Affiliated Company

In February 2007, we invested an aggregate of $370,000
in Holocom, Inc. (“Holocom”), a California corporation that manufactures products that protect information transmitted over
secure networks, in exchange for 2,100,000 shares of Series A Convertible Preferred Stock (“Series A Preferred Stock”), which
represented an approximate